QUANTIFY RESEARCH is a global partner to the pharmaceutical industry in close partnership with academia, patients, public institutions & clinical experts.
Real-world evidence & analytics
Quantify is the leading provider of RWE generated from the world-renouned Nordic data. Through our local presence, expert staff, institutional know-how and more than 10 years’ hands-on experience with the Nordic data, we offer an unparalleled ability to advise and execute Nordic RWE studies with local and global applications. Quantify has a successful track record of advising clients on securing Nordic ethical approval, data access, and optimizing analysis for commercial or regulatory purposes. We also offer RWE services in the EU, UK, and US.
Modelling, Access & Strategy
Quantify is a global provider of health economic evidence and a specialist provider of Nordic market access services including economic models, reimbursement dossiers, and strategic advice. Our experience and expertise ensures an optimized, streamlined market access process across the Nordics. For non-technical stakeholders, Quantify also develops value tools and visualisation dashboards to enhance communication. Our expert staff include ex-payers, ex-pharma, modelling experts, and experienced project managers.
Evidence review & synthesis
Quantify has long standing experience reviewing, interpreting and communicating evidence as part of targeted or systematic literature reviews (SLR). Our team ensures these activities are done systematically, with a focus on usability, to support knowledge management and commercialization activities. QUANTIFY is experienced in summarizing the results of this work through meta-analyses and narrative reviews. Our team consists of 50% PhDs and integrated AI solutions to provide our clients with the very best services.
Press
How will the EH HTA regulation and JCA affect Nordic pharma affiliates?
– Local affiliates may play an important role in the PICO simulation and scoping process : EU teams will rely on Nordic affiliates to provide local market information for PICO simulation and preparation.
Moreover, local affiliates may become an important point of influence for ‘health technology developers’ (HTDs) in the PICO process.
Involvement of the HTD in the scoping and PICO creation process, as currently drafted, is very limited.
If this set-up […]
Welcome Sara Hallum Søndergaard!
Quantify Research Denmark is growing!
Last week we welcomed Sara Hallum Søndergaard to the team in Copenhagen.
Sara has a background in public health and epidemiology from the University of Copenhagen (Københavns Universitet). Before joining Quantify Research, Sara worked as an epidemiologist at the Lægemiddelstyrelsen (Danish Medicines Agency) focusing on how to improve the use of real-world evidence in regulatory decision-making.
“I am very excited about […]
Hot off the press!
This month, Quantify Research’s Emilie Toresson Grip, Helena Skröder Löveborn and Oskar Ström published a study in Diabetes Care, using a uniquely collected NAFLD dataset (“HERALD”).
Using HERALD, the study showed that having or acquiring additional traits of metabolic syndromes increased the rate of progression to major adverse liver outcomes (MALO) in patients with T2D.
This information may be used to inform screening programs for MALO.
Read the full article here: […]
📣 FDA Approves rezdiffra, the first treatment for Nash/Mash📣
About a week ago, FDA approved the very first treatment for patients with liver fibrosis caused by fatty liver disease.
Rezdiffra (resmetirom) is now approved for treatment of adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), to be used along with diet and exercise.
While this is a significant milestone in the research area of NAFLD/NASH, many additional steps remain for all stakeholders in the field […]